How Much Does Rezdiffra (Resmetirom) Cost in Nebraska in 2026?

Nebraska Retail Pricing for Rezdiffra

The average cash-pay price for Rezdiffra at Nebraska retail pharmacies sits at $3,500 per month in 2026. This matches Madrigal Pharmaceuticals' national list price and applies whether a patient fills at a chain pharmacy in Omaha, a community pharmacy in Lincoln, or a specialty pharmacy serving rural counties.

Resmetirom is dispensed as an oral tablet taken once daily. The FDA approved Rezdiffra in March 2024 specifically for adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-advanced liver fibrosis, staged F2 or F3 1. Unlike injectable therapies, the oral dosing keeps administration costs limited to the drug itself, but the $42,000 annual price tag places it among the more expensive chronic liver disease treatments available. Nebraska patients paying cash should request pricing from multiple pharmacies, as specialty pharmacy networks occasionally negotiate slightly lower rates than independent retailers. The price has remained stable since launch, with no announced reductions through mid-2026.

Nebraska Medicaid Does Not Cover Rezdiffra

Nebraska's Medicaid program has not added Rezdiffra to its preferred drug list. Patients enrolled in Nebraska Medicaid, including those in Heritage Health managed care plans, cannot access resmetirom through their state benefit as of May 2026.

This exclusion affects a significant population. Nebraska had approximately 380,000 Medicaid enrollees in 2025, and MASH prevalence in the general population runs between 3% and 6% according to estimates from the American Association for the Study of Liver Diseases 2. The state's Medicaid Drug Utilization Review Board reviews new specialty medications periodically, but no public hearing on resmetirom has been scheduled. Patients on Medicaid who need treatment for progressive MASH fibrosis should discuss alternative approaches with their hepatologist, including vitamin E (for non-diabetic patients), pioglitazone, or GLP-1 receptor agonists that carry some evidence for liver fat reduction. The Madrigal savings card does not apply to government-funded insurance, so Medicaid patients cannot use it as a workaround 3.

Commercial Insurance Coverage in Nebraska

Several commercial insurers operating in Nebraska will cover Rezdiffra, though all require prior authorization and documented evidence of MASH with fibrosis staging.

Blue Cross Blue Shield of Nebraska, Medica, and UnitedHealthcare plans available through the state exchange have each published coverage criteria that align with the FDA label: biopsy-confirmed or imaging-confirmed MASH with fibrosis stage F2 or F3. Patients must typically demonstrate that they have tried lifestyle modification for at least 6 months before approval. A FibroScan score, MRI-PDFF measurement, or liver biopsy report dated within 12 months of the request strengthens authorization submissions.

Step therapy requirements vary. Some plans require documented failure of vitamin E or pioglitazone before approving resmetirom. Others accept the prescriber's clinical judgment that these alternatives are contraindicated or inappropriate. Copays for patients with commercial coverage and no manufacturer assistance typically range from $50 to $500 per month depending on formulary tier placement. Rezdiffra most commonly lands on Tier 4 or Tier 5 (specialty tier) across Nebraska commercial plans.

The Madrigal Pharmaceuticals Savings Card

Madrigal offers a copay assistance program that can reduce out-of-pocket costs to $0 per month for eligible patients with commercial insurance. The program has specific requirements that Nebraska patients should understand before relying on it.

Eligibility requires active commercial insurance (not Medicare, Medicaid, Tricare, or other government programs). The card covers the difference between the patient's copay and $0, up to a maximum annual benefit that Madrigal sets per calendar year. Patients activate the card through the Rezdiffra patient support website or by calling the dedicated access line. Nebraska pharmacies process it as a secondary payer at the point of sale.

One limitation: if a patient's insurer denies coverage entirely, the savings card typically does not apply to the full $3,500 monthly cost. It functions as copay reduction, not as a standalone discount program for uninsured patients. Madrigal does operate a separate patient assistance program for uninsured or underinsured patients who meet income thresholds, generally at or below 400% of the federal poverty level. Nebraska patients earning under approximately $62,400 annually (single household, 2026 FPL guidelines) may qualify for free medication through this route 4.

Compounded Resmetirom in Nebraska

Compounded resmetirom is available in Nebraska through licensed 503A compounding pharmacies. This is legal under federal law when a prescriber writes a patient-specific prescription and the pharmacy holds a valid Nebraska Board of Pharmacy compounding license.

503A pharmacies compound medications pursuant to individual prescriptions, as permitted under Section 503A of the Federal Food, Drug, and Cosmetic Act 5. Nebraska does not impose additional state-level restrictions beyond federal requirements for this category of compounding. The prescriber must determine that a compounded version is medically appropriate for the specific patient, which may involve documenting a clinical reason such as an allergy to an inactive ingredient in the branded product or a need for dose adjustment not available commercially.

Pricing for compounded resmetirom varies by pharmacy but is reported substantially lower than the branded product. Some 503A pharmacies advertise compounded thyroid hormone receptor beta agonists at a fraction of brand cost. Patients should verify that any compounding pharmacy they use is licensed by the Nebraska Department of Health and Human Services, holds current accreditation, and sources pharmaceutical-grade active ingredient from an FDA-registered supplier. Quality assurance differs between compounded products and FDA-approved drugs: compounded medications do not undergo the same bioequivalence testing, stability studies, or batch-level FDA inspection that Rezdiffra received during its approval process.

Clinical Evidence Supporting Resmetirom

The FDA approved resmetirom based primarily on the MAESTRO-NASH trial, a phase 3, randomized, double-blind, placebo-controlled study enrolling 966 patients with biopsy-confirmed MASH and fibrosis stages F1b through F3. At 52 weeks, 26% of patients receiving resmetirom 100 mg achieved fibrosis improvement of at least one stage without worsening of NASH, compared to 14% of placebo patients (P<0.001) 6.

The co-primary endpoint of NASH resolution without worsening fibrosis was met by 30% of the 100 mg group versus 10% of placebo. Liver fat reduction measured by MRI-PDFF averaged 22.9% absolute decrease from baseline in the treatment arm. These results positioned resmetirom as the first medication to receive FDA approval specifically for MASH, a disease that previously had no approved pharmacotherapy despite affecting an estimated 6 to 8 million Americans with progressive fibrosis 7.

Dr. Stephen Harrison, principal investigator of MAESTRO-NASH, stated: "This is the first time we have demonstrated that a drug can improve the underlying liver histology in MASH patients with significant fibrosis, addressing both the inflammatory and fibrotic components of the disease."

Safety data from the trial showed the most common adverse events were diarrhea (27% vs. 18% placebo) and nausea (13% vs. 8% placebo), with most gastrointestinal symptoms resolving within the first 4 weeks of treatment. The FDA label carries a warning about potential drug interactions with statins, as resmetirom increases LDL receptor expression and can amplify statin effects on LDL cholesterol reduction.

Telehealth Access in Nebraska

Nebraska permits telehealth prescribing of Rezdiffra. Patients anywhere in the state can receive a resmetirom prescription through a video or audio visit with a licensed prescriber, provided the clinician establishes an appropriate patient-provider relationship and documents the MASH diagnosis with supporting evidence.

Nebraska's Telehealth Act (LB 400, updated 2024) requires that the prescribing provider hold an active Nebraska medical license or participate in an interstate compact that covers Nebraska 8. The initial evaluation for MASH typically requires laboratory work (ALT, AST, metabolic panel, lipid panel) and imaging (FibroScan or MRI), which patients complete locally before the telehealth visit. Follow-up monitoring at 3 and 6 months, including repeat liver function tests and assessment of gastrointestinal tolerability, can also occur via telehealth.

For Nebraska patients in rural counties without nearby hepatologists or gastroenterologists, telehealth removes a significant access barrier. The state has 93 counties, and many lack specialty liver disease clinics. Patients in the Panhandle, Sandhills, or southwest Nebraska who previously faced 3- to 4-hour drives for hepatology appointments can now access evaluation and ongoing management remotely. The prescription itself routes to any pharmacy licensed to dispense in Nebraska, including specialty mail-order pharmacies that deliver statewide.

How to Reduce Your Rezdiffra Cost in Nebraska

Multiple strategies exist for lowering out-of-pocket resmetirom costs, and most Nebraska patients should layer them.

First, confirm insurance coverage. Call the number on your insurance card and ask specifically about Rezdiffra (NDC and product details in hand). Request the prior authorization criteria in writing. Your prescriber's office may have a benefits investigation team or can use Madrigal's hub services to run a benefits check before submitting the prescription.

Second, apply for the Madrigal savings card simultaneously. Even if your insurance covers Rezdiffra, your specialty tier copay could be $200 to $500 monthly without assistance. The savings card stacks on top of commercial coverage to eliminate or reduce that copay.

Third, if you are uninsured or underinsured, apply for Madrigal's patient assistance program directly. Income documentation and a signed prescriber certification are required.

Fourth, discuss compounded resmetirom with your provider if branded access remains cost-prohibitive. Your hepatologist should weigh the cost savings against the limitations of compounded products, particularly the absence of FDA-level bioequivalence data.

The Endocrine Society's 2024 guidelines on thyroid hormone receptor agonists note that "access programs should be utilized early in the prescribing process to avoid treatment delays in patients with progressive fibrotic liver disease" 9.

Who Should Consider Rezdiffra in Nebraska

Resmetirom is indicated for adults with MASH and liver fibrosis stages F2 or F3. Not every patient with fatty liver disease is a candidate. The drug targets a specific population: those whose liver biopsies or validated non-invasive tests confirm both steatohepatitis (active inflammation) and clinically significant fibrosis.

Patients with compensated cirrhosis (F4) were not included in the key trial and are not covered by the current FDA indication. Similarly, patients with simple steatosis (fatty liver without inflammation) or minimal fibrosis (F0-F1) should not receive resmetirom based on available evidence. Nebraska prescribers should document fibrosis staging clearly, as this documentation serves dual purposes: clinical appropriateness and insurance authorization.

The AASLD practice guidance updated in 2024 recommends considering pharmacotherapy for MASH patients with fibrosis stage F2 or higher, particularly those who have not responded to sustained lifestyle intervention over 6 to 12 months 10. Weight loss of 7% to 10% of body weight remains the first-line intervention, as multiple trials have demonstrated histological improvement at these thresholds. Resmetirom enters the algorithm when lifestyle measures prove insufficient or when fibrosis progression raises urgency.

Nebraska's obesity prevalence of 36.2% (CDC BRFSS 2024) places the state above the national average and suggests a substantial at-risk population for MASH progression 11. Combined with high rates of type 2 diabetes and metabolic syndrome in the state's adult population, demand for MASH-directed therapy is likely to grow in coming years.